Please provide your email address to receive an email when new articles are posted on . The effects of two annual 4-mg doses of intravenous zoledronate in HIV-infected men linger for at least 5 years ...

Infrequent zoledronate dosing may reduce the risk for fracture over 10 years in postmenopausal women, while preserving bone mineral density.

Credit: Shutterstock. The researchers found that a fragility fracture occurred in 190 women in the placebo group and 122 women in the zoledronate group (hazard ratio [HR] with zoledronate, 0.63).

MESSINA, Italy — Although the bisphosphonate zoledronic acid, or zoledronate (Aclasta, Reclast, Novartis), stops bone loss in patients with osteoporosis, it also ups levels of the protein biomarker ...

The researchers found that 6.3, 6.6, and 11.1% of the zoledronate-zoledronate, zoledronate-placebo, and placebo-placebo groups, respectively, had a new morphometric fracture at follow-up. HealthDay ...

With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...

June 7, 2011 (Boston, Massachusetts) — Lower doses than are currently prescribed of the bisphosphonate zoledronate may be enough to increase bone density and reduce bone resorption in postmenopausal ...

Women aged at least 65 years with osteopenia were shown to be less at risk for fragility fracture when treated with zoledronate vs. placebo, according to study results reported at the American Society ...

To counter the decline in BMD after denosumab treatment is discontinued, osteoporosis patients may be transitioned from denosumab to other anti-resorptives. This report investigates whether a single ...

FGFR and FGF ligand overexpression in lung cancer: Implications for targeted therapy. Effect of lymphoid tissue inducer cells on lymphatic tumor cell invasion via activation of the RANKL/RANK axis ...

Joo Hwan No, Fernando de Macedo Dossin, Yonghui Zhang, Yi-Liang Liu, Wei Zhu, Xinxin Feng, Jinyoung Anny Yoo, Eunhae Lee, Ke Wang, Raymond Hui, Lucio H. Freitas-Junior, Eric Oldfield Proceedings of ...

The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Recurrent Fracture trial was an international, multicenter, randomized, double-blind, placebo-controlled trial of ...